Combo Product Firms Should Follow Specialty Pharma Model – Angiotech
This article was originally published in The Gray Sheet
Executive Summary
Angiotech Pharmaceuticals believes the best way to commercially exploit drug/device combination products is to act like a specialty pharmaceutical firm instead of a device company
You may also be interested in...
Vascular Wrap Tied To Angiotech Escaping Boston Scientific’s Shadow
Angiotech expects sales of its Vascular Wrap paclitaxel-eluting mesh for bypass procedures to help decrease its reliance on revenue from its partnership with Boston Scientific for theTaxus drug-eluting stent
Vascular Wrap Tied To Angiotech Escaping Boston Scientific’s Shadow
Angiotech expects sales of its Vascular Wrap paclitaxel-eluting mesh for bypass procedures to help decrease its reliance on revenue from its partnership with Boston Scientific for theTaxus drug-eluting stent
Angiotech Looks Beyond Stents To Other Anti-Scarring Treatments
Angiotech will begin studies evaluating paclitaxel for elbow and knee injuries in an effort to diversify its product offerings starting in the third quarter